sacituzumab
gilead sciences
['breast', 'sacituzumab', 'sacitu, govi', 'bcsm']
os (modestly) improved with sacituzumab govitecan over tpc in metastatic hr+her2- breast cancer (11.2 to 14.4 mo). an incremental improvement #esmo22 #bcsm 
Breast Medical Oncologist - @MayoClinic. Focus on #TNBC and #immunoonc. Opinions are mine, not my employer’s. Orgullosamente ecuatoriano ????